当前位置： SCI文献检索 > ADVANCES IN THERAPY期刊下所有文献 > Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors.

Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors.

Abstract：

:In the last few years, immunotherapy has transformed the way we treat solid tumors, including melanoma, lung, head neck, breast, renal, and bladder cancers. Durable responses and long-term survival benefit has been experienced by many cancer patients, with favorable toxicity profiles of immunotherapeutic agents relative to chemotherapy. Cures have become possible in some patients with metastatic disease. Additional approvals of immunotherapy drugs and in combination with other agents are anticipated in the near future. Multiple additional immunotherapy drugs are in earlier stages of clinical development, and their testing in additional tumor types is under way. Despite considerable early success and relatively fewer side effects, the majority of cancer patients do not respond to checkpoint inhibitors. Additionally, while the drugs are generally well tolerated, there is still the potential for significant, unpredictable and even fatal toxicity with these agents. Improved biomarkers may help to better select patients who are more likely to respond to these drugs. Two key biologically important predictive tissue biomarkers, specifically, PD-L1 and mismatch repair deficiency, have been FDA-approved in conjunction with the checkpoint inhibitor, pembrolizumab. Tumor mutation burden, another promising biomarker, is emerging in several tumor types, and may also soon receive approval. Finally, several other tissue and liquid biomarkers are emerging that could help guide single-agent immunotherapy and in combination with other agents. Of these, one promising investigational biomarker is alteration or deficiency in DNA damage response (DDR) pathways, with altered DDR observed in a broad spectrum of tumors. Here, we provide a critical overview of current, emerging, and investigational biomarkers in the context of response to immunotherapy in solid tumors.

journal_name

Adv Ther

journal_title

Advances in therapy

authors

Arora S,Velichinskii R,Lesh RW,Ali U,Kubiak M,Bansal P,Borghaei H,Edelman MJ,Boumber Y

doi

10.1007/s12325-019-01051-z

subject

Has Abstract

pub_date

2019-10-01 00:00:00

pages

2638-2678

issue

eissn

0741-238X

issn

1865-8652

pii

10.1007/s12325-019-01051-z

journal_volume

pub_type

杂志文章,评审

在线工具

Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors.